| Literature DB >> 35740230 |
Maria Obreja1,2, Egidia Gabriela Miftode1,2, Iulian Stoleriu3, Daniela Constantinescu2,4, Andrei Vâță1,2, Daniela Leca1,2, Corina Maria Cianga2,4, Olivia Simona Dorneanu1,2, Mariana Pavel-Tanasa2,4, Petru Cianga2,4.
Abstract
The empirical administration of antibiotics for suspected bacterial meningitis denotes a poor bacterial stewardship. In this context, the use of biomarkers can distinguish between bacterial and viral infections before deciding treatment. Our study assesses how levels of heparin-binding protein (HBP), neutrophil gelatinase-associated lipocalin (NGAL), S100 calcium-binding protein B (S100B), and neuron-specific enolase (NSE) in cerebrospinal fluid (CSF) and in blood can promptly confirm bacterial etiology and the need for antibiotic treatment. The CSF and blood levels of HBP, NGAL, S100B, and NSE of 81 patients with meningitis were measured and analyzed comparatively. Statistical sensitivity, specificity, and positive and negative predictive values were evaluated. CSF levels of HBP and NGAL and the blood level of S100B in the bacterial meningitis group were significantly higher (p < 0.05). The area under curve (AUC) for predicting bacterial meningitis was excellent for the CSF level of HBP (0.808 with 93.54% sensitivity and 80.64% specificity), good for the CSF level of NGAL (0.685 with 75.00% sensitivity and 65.62% specificity), and good for the blood level of S100B (0.652 with 65.90% sensitivity and 57.14% specificity). CSF levels of HBP and NGAL, as well as the blood level of S100B, could help discriminate between bacterial and viral meningitis before considering antibiotic treatment.Entities:
Keywords: HBP; NGAL; NSE; S100B; bacterial meningitis; biomarkers
Year: 2022 PMID: 35740230 PMCID: PMC9220165 DOI: 10.3390/antibiotics11060824
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
General characteristics of patients.
| Bacterial | Viral | Total | |
|---|---|---|---|
| Age (years), mean ± SD | 52.72 ± 20.03 | 57.20 ± 16.60 | 54.69 ± 18.69 |
| Onset (days), mean ± SD | 4.14 ± 3.41 | 4.73 ± 5.32 | 4.39 ± 4.30 |
| Hospitalization (days), mean ± SD | 18.74 ± 11.35 | 15.74 ± 6.13 | 17.48 ± 9.58 |
Risk factors for bacterial meningitis.
| Bacterial Meningitis | Viral | Total | OR | 95% CI | ||
|---|---|---|---|---|---|---|
| Sex, | 29(61.7) | 22(64.7) | 51(63.0) | 0.782 | 1.13 | 0.455–2.846 |
| Area, | 29(61.7) | 17(50.0) | 46(56.8) | 0.294 | 1.61 | 0.659–3.936 |
| Risk factors | 21(44.7) | 12(35.3) | 33(40.7) | 0.396 | 1.48 | 0.597–3.673 |
Clinical signs and symptoms.
| Clinical Signs and Symptoms | Bacterial Meningitis | Viral | Total | OR | 95% CI | |
|---|---|---|---|---|---|---|
| Altered mental status (%) | 28(59.6) | 16(47.1) | 44(54.3) | 0.264 | 1.65 | 0.681–4.039 |
| Fever (%) | 40(85.1) | 25(73.5) | 65(80.2) | 0.197 | 2.05 | 0.680–6.223 |
| Headache (%) | 43(91.5) | 27(79.4) | 70(86.4) | 0.117 | 2.78 | 0.745–10.427 |
| Vomiting (%) | 8(17.0) | 7(20.6) | 15(18.5) | 0.683 | 0.79 | 0.256–2.442 |
| Photophobia (%) | 2(4.3) | 6(11.8) | 8(7.4) | 0.203 | 0.33 | 0.057–1.937 |
| Nuchal rigidity (%) | 39(83.0) | 28(82.4) | 67(82.7) | 0.941 | 1.04 | 0.326–3.347 |
| Brudzinsky sign (%) | 24(51.1) | 14(41.2) | 38(46.9) | 0.379 | 1.49 | 0.612–3.633 |
| Kernig sign (%) | 18(38.3) | 10(29.4) | 28(34.6) | 0.407 | 1.49 | 0.580–3.827 |
| CT (%) | 29(61.7) | 23(67.6) | 52(64.2) | |||
| CT lesions (%) | 19(40.4) | 12(35.3) | 31(38.3) | 0.639 | 1.24 | 0.499–3.101 |
CT, computer tomography; OR, odds ratio.
Paraclinical blood test results.
| Paraclinical | Bacterial | Viral | Total | |
|---|---|---|---|---|
| WBC (cmm) | 15,573 ± 7561 | 11,708 ± 4546 | 13,951 ± 6714 | 0.020 |
| PMN (%) | 82.92 ± 10.21 | 77.62 ± 11.87 | 80.70 ± 11.18 | 0.034 |
| Ly (%) | 9.8 ± 8.1 | 14.07 ± 8.7 | 11.60 ± 8.6 | 0.011 |
| CRP (mg/dL) | 122.29 ± 104.25 | 47.62 ± 91.97 | 91.92 ± 105.33 | 0.000 |
| ESR (mm/h) | 62.73 ± 41.33 | 38.46 ± 34.18 | 52.62 ± 40.11 | 0.007 |
| Fib (g/L) | 5.16 ± 2.46 | 4.28 ± 4.40 | 4.82 ± 3.33 | 0.017 |
| Hb (g/dL) | 12.68 ± 2.14 | 12.52 ± 2.34 | 12.62 ± 2.21 | 0.837 |
| PLT (mcL) | 229,172 ± 141,070 | 258,411 ± 123,505 | 241,445 ± 133,962 | 0.139 |
| Urea (mg/dL) | 46.69 ± 42.52 | 51.55 ± 29.11 | 48.73 ± 37.35 | 0.155 |
| Creatinine (mg/dL) | 0.95 ± 0.46 | 1.09 ± 0.41 | 1.01 ± 0.44 | 0.046 |
| Glucosemg/dL) | 183.52 ± 118.02 | 146.75 ± 6819 | 168.16 ± 101.37 | 0.122 |
| ALT (U/L) | 58.80 ± 46.38 | 143.95 ± 543.40 | 94.55 ± 353.31 | 0.358 |
| AST (U/L) | 67.69 ± 79.27 | 117.08 ± 398.73 | 88.68 ± 265.69 | 0.138 |
| Bil (mg/dL) | 1.19 ± 0.86 | 0.95 ± 0.70 | 1.09 ± 0.80 | 0.061 |
WBC, white blood cells; PMN, polymorphonuclear cells; Ly, lymphocyte cells; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Fib, fibrinogen; Hb, hemoglobin; PLT, platelets cells; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Bil, bilirubin.
HBP, NGAL, S100B, NSE values in CSF and blood.
| Studied Biomarkers | Bacterial | Viral | Total | |
|---|---|---|---|---|
| HBP in CSF (ng/mL) | 66.00 ± 134.50 | 2.38 ± 5.63 | 39.90 ± 107.59 | 0.000 |
| NGAL in CSF (pg/mL) | 11,029.39 ± 12,231.18 | 8224.67 ± 13,492.39 | 9822.30 ± 12,781.35 | 0.008 |
| S100B in CSF (ng/mL) | 1901.99 ± 3663.14 | 951.94 ± 1549.94 | 1493.11 ± 2968.15 | 0.189 |
| NSE in CSF (ng/mL) | 4674.22 ± 6589.24 | 2899.22 ± 3034.87 | 3910.29 ± 5401.04 | 0.108 |
| HBP in blood (ng/mL) | 4.86 ± 6.71 | 18.88 ± 58.13 | 10.87 ± 38.69 | 0.342 |
| NGAL in blood (pg/mL) | 5888.67 ± 5816.67 | 12,532.63 ± 15,461.81 | 8736.08 ± 11,434.83 | 0.303 |
| S100B in blood (ng/mL) | 166.30 ± 210.05 | 92.04 ± 130.15 | 134.48 ± 182.93 | 0.028 |
| NSE in blood (ng/mL) | 4053.48 ± 2843.24 | 3145.32 ± 2031.94 | 3664.27 ± 2552.83 | 0.189 |
CSF, cerebrospinal fluid; HBP, heparin-binding protein; NGAL, neutrophil gelatinase-associated lipocalin; S100B, calcium-binding protein B; NSE, neuron-specific enolase.
AUC for all biomarkers (HBP, NGAL, S100B, NSE) in CSF and blood.
| Studied Biomarkers | AUC | SE | 95%CI | |
|---|---|---|---|---|
| HBP in CSF | 0.808 | 0.50 | 0.000 | 0.709–0.907 |
| NGAL in CSF | 0.685 | 0.67 | 0.008 | 0.553–0.816 |
| S100B in CSF | 0.591 | 0.68 | 0.189 | 0.457–0.725 |
| NSE in CSF | 0.611 | 0.68 | 0.108 | 0.478–0.745 |
| HBP in blood | 0.434 | 0.69 | 0.342 | 0.299–0.569 |
| NGAL in blood | 0.409 | 0.71 | 0.189 | 0.270–0.548 |
| S100B in blood | 0.652 | 0.66 | 0.028 | 0.523–0.780 |
| NSE in blood | 0.597 | 0.68 | 0.160 | 0.465–0.730 |
CSF, cerebrospinal fluid; HBP, heparin-binding protein; NGAL, neutrophil gelatinase-associated lipocalin; S100B, S100 calcium-binding protein B; NSE, neuron-specific enolase; AUC, area under curve; SE, standard error.
Statistical evaluation of biomarkers (HBP, NGAL, S100B, NSE) in CSF and blood.
| Studied Biomarkers | Cut-Off | Se | Sp | PPV | NPV |
|---|---|---|---|---|---|
| HBP in CSF (ng/mL) | 2.47 | 93.54 | 80.64 | 82.84 | 67.56 |
| NGAL in CSF (ng/mL) | 4996.00 | 75.00 | 65.62 | 73.17 | 67.74 |
| S100B in CSF (ng/mL) | 540.99 | 63.88 | 50.00 | 56.09 | 58.06 |
| NSE in CSF (ng/mL) | 2216.25 | 66.66 | 56.25 | 63.41 | 58.06 |
| HBP in blood (ng/mL) | 2.37 | 55.26 | 41.17 | 52.50 | 45.16 |
| NGAL in blood (pg/mL) | 3368.00 | 53.84 | 48.07 | 34.14 | 80.64 |
| S100B in blood (ng/mL) | 36.24 | 65.90 | 57.14 | 70.73 | 51.61 |
| NSE in blood (ng/mL) | 4984.92 | 56.09 | 67.74 | 69.69 | 53.84 |
CSF, cerebrospinal fluid; HBP, heparin-binding protein; NGAL, neutrophil gelatinase-associated lipocalin; S100B, S100 calcium-binding protein B; NSE, neuron-specific enolase; Se, sensitivity; Sp, specificity; PPV, positive predictive value; NPV, negative predictive value.
Figure 1ROC curves for various associations of biomarkers. Model 1 comprises the values of HBP and NGAL in CSF and S100B in blood, model 2 comprises the values of HBP in CSF and S100B in blood, while model 3 relies on the significant biomarkers identified during the paraclinical blood tests (WBC, PMN, Ly, CRP, ESR, Fib, creatinine). The AUC values > 0.9 define an outstanding discrimination, while the AUC values between 0.8 and 0.9 denote an excellent capacity for the prediction models [24].